Stock DNA
Pharmaceuticals & Biotechnology
USD 8 Million ()
NA (Loss Making)
NA
0.00%
-0.58
-319.55%
1.24
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2023)
Net Profit:
-5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-28.83%
0%
-28.83%
6 Months
-41.41%
0%
-41.41%
1 Year
-82.92%
0%
-82.92%
2 Years
-97.58%
0%
-97.58%
3 Years
-85.13%
0%
-85.13%
4 Years
-99.64%
0%
-99.64%
5 Years
0%
0%
0.0%
Mainz Biomed NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.80%
EBIT Growth (5y)
-302.00%
EBIT to Interest (avg)
-16.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.63%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.31
EV to EBIT
-0.22
EV to EBITDA
-0.23
EV to Capital Employed
1.84
EV to Sales
4.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-831.05%
ROE (Latest)
-319.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 1 Schemes (0.01%)
Foreign Institutions
Held by 5 Foreign Institutions (0.1%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.90
0.90
Operating Profit (PBDIT) excl Other Income
-17.40
-25.60
32.03%
Interest
1.10
0.30
266.67%
Exceptional Items
-2.30
0.70
-428.57%
Consolidate Net Profit
-21.70
-26.30
17.49%
Operating Profit Margin (Excl OI)
-20,602.30%
-29,754.70%
915.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 80.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.49% vs 0.38% in Dec 2023
About Mainz Biomed NV 
Mainz Biomed NV
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






